Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case

Biswas, Rituparna; Halder, Anirban; Gangopadhyay, Mimi; Biswas, Dipanwita

doi:10.1186/s43046-020-00038-0

Cited by 6 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another case report of a 48-year-old patient with inoperable maxillary sinus IMT with complete response after concomitant radiotherapy and prednisone have been published. In this context, combination of radiotherapy with steroids appears to be an effective alternative in non-operable maxillary IMT [ 29 ].…”

Section: Current Treatmentsmentioning

confidence: 99%

Inflammatory Myofibroblastic Tumour: State of the Art

Gros

Tos

Jones

et al. 2022

Cancers

View full text Add to dashboard Cite

An inflammatory myofibroblastic tumor (IMT) is a neoplasm composed of myofibroblastic and fibroblastic spindle cells accompanied by inflammatory cells, including lymphocytes and eosinophils. It is an ultra-rare tumor, the optimal management of which remains to be defined. Surgery is the treatment of choice for localized tumors. The treatment of advanced disease is not precisely defined. Chemotherapy regimens result in an overall response rate of approximately 50% based on retrospective data. The latest pathophysiological data highlight the role played by tyrosine kinase fusion genes in IMT proliferation. Anaplast lymphoma kinase (ALK) oncogenic activation mechanisms have been characterized in approximately 80% of IMTs. In this context, data regarding targeted therapies are most important. The aims of this article are to review the latest published data on the use of systematic therapy, particularly the use of molecular targeted therapy, and to publish an additional case of an IMT with Ran-binding protein 2 (RANPB2)-ALK fusion showing a long response to a tyrosine kinase inhibitor.

show abstract

Section: Current Treatmentsmentioning

confidence: 99%

Inflammatory Myofibroblastic Tumour: State of the Art

Gros

Tos

Jones

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Furthermore, based on our results, postoperative radiotherapy can benefit HNIMT with malignant transformation as well as patients with a high risk of malignant transformation. Although surgery remains the main option for IMT treatment, 1 there are sporadic case reports about successful treatment by radiotherapy in IMT located in the maxillary sinus 24 and trachea. 25 However, the effectiveness of radiotherapy for IMT treatment has not been verified through randomized controlled trials.…”

Section: Discussionmentioning

confidence: 99%

A clinical signature predicting the malignant transformation of inflammatory myofibroblastic tumor in the head and neck

Peng

Chen

Liu

et al. 2022

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Background: Inflammatory myofibroblastic tumors in the head and neck (HNIMTs) sometimes show aggressive clinical features and can be diagnosed as HNIMT with malignant transformation. Methods:The clinicopathological features of 45 HNIMTs with or without malignant transformation were retrospectively investigated. Logistic regression and receiver operating characteristic analysis were used to establish the predictive model.Results: HNIMT with malignant transformation was associated with worse prognosis.HNIMT with a tumor size of >4.4 cm, tumors located in the maxillary sinus, or a preoperative neutrophil-to-lymphocyte ratio (NLR) greater than 1.958 were associated with higher chance of malignant transformation, with an AUC value of 0.9189.Postoperative radiotherapy could benefit HNIMT patients with high risk of malignant transformation.Conclusions: HNIMT patients with a tumor size of >4.4 cm, tumors located in the maxillary sinus, and a preoperative NLR over 1.958 were associated with a higher risk of malignant transformation. These patients can benefit from postoperative radiotherapy.

show abstract

“…The majority of patients had stable disease after treatment. Another report showed a case of a patient with IMT of the head and neck that invaded maxillary sinus [ 169 ]. Due to the unresectability of the tumour, he underwent definitive radiotherapy with a dose of 60 Gy in conventional 2 Gy fractions over 6 weeks, concurrently with oral prednisolone.…”

Section: Radiotherapymentioning

confidence: 99%

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

CHMIEL,

SłOWIKOWSKA,

BANASZEK

et al. 2024

View full text Add to dashboard Cite

Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.

show abstract

Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case

Cited by 6 publications

References 6 publications

Inflammatory Myofibroblastic Tumour: State of the Art

Inflammatory Myofibroblastic Tumour: State of the Art

A clinical signature predicting the malignant transformation of inflammatory myofibroblastic tumor in the head and neck

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

Contact Info

Product

Resources

About